Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM EDTUBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.
Analyst Marc Goodman notes a cautious outlook on the shares as... More
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM EDTLeerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results
Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.
... MoreMorgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM EDTMorgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $58.24 Friday.
... MoreBarclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM EDTBarclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).
Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More
